NasdaqGS:ARAY - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
6/30/2026	486	16	N/A	N/A	2
6/30/2025	456	0	N/A	N/A	4
6/30/2024	434	-16	N/A	N/A	4
3/31/2024	431	-21	-24	-13	N/A
12/31/2023	447	-15	8	20	N/A
9/30/2023	455	-7	-6	7	N/A
6/30/2023	448	-9	3	16	N/A
3/31/2023	439	-10	-4	2	N/A
12/31/2022	417	-12	-50	-44	N/A
9/30/2022	419	-10	2	6	N/A
6/30/2022	430	-5	-7	-2	N/A
3/31/2022	431	-13	4	8	N/A
12/31/2021	437	-12	43	46	N/A
9/30/2021	418	-8	30	33	N/A
6/30/2021	396	-6	36	39	N/A
3/31/2021	380	5	49	51	N/A
12/31/2020	377	8	21	23	N/A
9/30/2020	379	14	17	20	N/A
6/30/2020	383	4	-5	-1	N/A
3/31/2020	405	3	-15	-11	N/A
12/31/2019	409	-1	-11	-6	N/A
9/30/2019	413	-17	-40	-36	N/A
6/30/2019	419	-16	-34	-30	N/A
3/31/2019	415	-16	-16	-11	N/A
12/31/2018	412	-24	-6	0	N/A
9/30/2018	410	-24	6	14	N/A
6/30/2018	405	-24	12	18	N/A
3/31/2018	403	-28	7	14	N/A
12/31/2017	401	-24	N/A	-3	N/A
9/30/2017	388	-29	N/A	-7	N/A
6/30/2017	383	-30	N/A	0	N/A
3/31/2017	366	-32	N/A	-4	N/A
12/31/2016	374	-26	N/A	0	N/A
9/30/2016	396	-22	N/A	12	N/A
6/30/2016	399	-26	N/A	31	N/A
3/31/2016	406	-24	N/A	7	N/A
12/31/2015	398	-28	N/A	17	N/A
9/30/2015	387	-32	N/A	10	N/A
6/30/2015	380	-40	N/A	-14	N/A
3/31/2015	380	-44	N/A	-13	N/A
12/31/2014	380	-46	N/A	0	N/A
9/30/2014	375	-42	N/A	-3	N/A
6/30/2014	369	-35	N/A	0	N/A
3/31/2014	352	-44	N/A	-3	N/A
12/31/2013	326	-71	N/A	-37	N/A
9/30/2013	310	-91	N/A	-64	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ARAYは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.4% ) よりも高い成長率であると考えられます。

収益対市場: ARAY今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: ARAY今後 3 年以内に収益を上げることが予想されます。

収益対市場: ARAYの収益 ( 5.4% ) US市場 ( 8.7% ) よりも低い成長が予測されています。

高い収益成長: ARAYの収益 ( 5.4% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ARAYの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Accuray 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Forecast breakeven date pushed back to 2026

Analysts Have Lowered Expectations For Accuray Incorporated (NASDAQ:ARAY) After Its Latest Results

Price target decreased by 11% to US$7.75

Accuray Incorporated Provides Earnings Guidance for the Year 2024

Accuray Incorporated Reaffirms Revenue Guidance for the Third Quarter and Full Fiscal Year 2024

Recent updates

Accuray Incorporated Announces Approval of the Accuray Precision Treatment Planning System by China's National Medical Products Administration

Forecast breakeven date pushed back to 2026

Independent Chairman of the Board recently bought US$156k worth of stock

Lacklustre Performance Is Driving Accuray Incorporated's (NASDAQ:ARAY) 25% Price Drop

Accuray Incorporated Announces Executive Changes, Effective May 17, 2024

Analysts Have Lowered Expectations For Accuray Incorporated (NASDAQ:ARAY) After Its Latest Results

Price target decreased by 11% to US$7.75

Are Investors Undervaluing Accuray Incorporated (NASDAQ:ARAY) By 25%?

Accuray Incorporated Provides Earnings Guidance for the Year 2024

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Now 35% undervalued after recent price drop

Accuray Incorporated Showcases Advances in Radiation Therapy Solutions Designed to Improve the Cancer Treatment Experience at ESTRO 2024

Accuray Incorporated to Report Q3, 2024 Results on May 01, 2024

Accuray Getting Very Little Love Ahead Of A Coming Revenue Ramp

Accuray Incorporated Announces New Data from Two Clinical Studies Indicate High-Risk and Recurrent Prostate Cancers Can Be Effectively Treated in 5 Days Using the Accuray CyberKnife System

New minor risk - Shareholder dilution

Is Accuray (NASDAQ:ARAY) A Risky Investment?

Second quarter 2024 earnings: EPS misses analyst expectations

Accuray Incorporated Reaffirms Revenue Guidance for the Third Quarter and Full Fiscal Year 2024

Accuray Incorporated to Report Q2, 2024 Results on Jan 31, 2024

President recently sold US$162k worth of stock

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

President recently sold US$99k worth of stock

Accuray Incorporated to Report Q1, 2024 Results on Nov 07, 2023

Accuray Announces Approval of the Tomo C Radiation Treatment Delivery System by China's National Medical Products Administration

Accuray Incorporated, Annual General Meeting, Nov 09, 2023

Why Investors Shouldn't Be Surprised By Accuray Incorporated's (NASDAQ:ARAY) 26% Share Price Plunge

Full year 2023 earnings: EPS misses analyst expectations

Forecast breakeven date pushed back to 2025

Accuray Incorporated Provides Revenue Guidance for Fiscal Year 2024

Accuray Incorporated to Report Q4, 2023 Results on Aug 09, 2023

President recently sold US$65k worth of stock

Insider recently sold US$93k worth of stock

Accuray Incorporated Announces New Data Presented at the European Society for Radiotherapy and Oncology

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

These 4 Measures Indicate That Accuray (NASDAQ:ARAY) Is Using Debt Extensively

The Return Trends At Accuray (NASDAQ:ARAY) Look Promising

Accuray Incorporated Announces Data from Randomized, Multicenter Trial PACE-A

High number of new directors

Accuray Incorporated Reiterates Earnings Guidance for the Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Accuray Incorporated Announces the Appointment of Robert C. Kill to its Board of Directors

Accuray Incorporated to Report Q2, 2023 Results on Feb 01, 2023

Accuray Incorporated Announces First Patient Treatments in New Zealand with the CyberKnife(R) System

Accuray Incorporated Announces Intent to Resign from Position as Chief Accounting Officer and Principal Accounting Officer, Effective January 3, 2023

Accuray (NASDAQ:ARAY) Takes On Some Risk With Its Use Of Debt

First quarter 2023 earnings: EPS and revenues miss analyst expectations

President recently sold US$76k worth of stock

Accuray Incorporated Re-Affirms Guidance for Year 2023

Accuray Announces Tomo C Registration Submission to China's National Medical Products Administration

High number of new directors

Accuray (NASDAQ:ARAY) Is Doing The Right Things To Multiply Its Share Price

Japanese Ministry of Health, Labor and Welfare Approves Reimbursement for the Cyberknife(R) System for the Treatment of Trigeminal Neuralgia

Accuray Incorporated to Report Q1, 2023 Results on Nov 02, 2022

Accuray Incorporated Announces Data Published in The Lancet Oncology Indicate Men With Prostate Cancer Treated With the Accuray CyberKnife® Platform Experienced a Lower Incidence of Bladder Side Effects Than Those Treated With Conventional Linear Accelerators

Accuray Incorporated, Annual General Meeting, Nov 10, 2022

Accuray launches CyberKnife platform in Africa for cancer patients

Richard R. Pettingill Not to Stand for Re-Election as Class I Director of Accuray Incorporated

Accuray Incorporated Appoints Seth Blacksburg as Chief Medical Officer

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Accuray Incorporated Provides Revenue Guidance for Year 2023

Accuray GAAP EPS of -$0.04 beats by $0.03, revenue of $110.02M beats by $4.7M

Accuray Incorporated to Report Q4, 2022 Results on Aug 10, 2022

Accuray CyberKnife® System Real World Data and Clinical Studies Show Benefits in Treatment of Neurological Indications

Here's Why Accuray (NASDAQ:ARAY) Has A Meaningful Debt Burden

Accuray Incorporated(NasdaqGS:ARAY) dropped from Russell 3000E Index

Accuray Incorporated Appoints Franco N. Palomba as Chief Accounting Officer & Controller

Accuray (NASDAQ:ARAY) Might Have The Makings Of A Multi-Bagger

High number of new directors

Accuray: Nothing Special